Acknowledgements:
The authors would like to thank all the patients and investigators that participated in the studies. The author would like to thank John N. Ratchford for his contributions to the inebilizumab program. The authors would like to acknowledge Kamille O’Connor, Xiaoying Yu and Rouletta Blowers of Amador Bioscience (Pleasanton, CA, USA) for assistance with preparation of this manuscript.